Search
for
Sort by
Research 331–360 of 1000+
- Post-finasteride syndrome - a true clinical entity?
- Androgenetic alopecia – Current status
- SRD5A2 and emerging therapies in androgen-driven disorders
- A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function
- Identification of a Rare Variant in the <i>SRD5A2</i> Gene in Siblings With 46,XY Disorders of Sexual Development
- Male Androgenetic Alopecia
- Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study
- Hormonal and Genetic Etiology of Male Androgenetic Alopecia
- Stauntonia hexaphylla Extract Ameliorates Androgenic Alopecia by Inhibiting Androgen Signaling in Testosterone-induced Alopecia Mice
- Immune and Non-immune Interactions in the Pathogenesis of Androgenetic Alopecia
- Physcion, a novel inhibitor of 5α-reductase that promotes hair growth in vitro and in vivo
- Androgenetic alopecia
- Ent-kaurane-type diterpenoids from Isodonis Herba activate human hair follicle dermal papilla cells proliferation via the Akt/GSK-3β/β-catenin transduction pathway
- Early embryonic exposure of freshwater gastropods to pharmaceutical 5-alpha-reductase inhibitors results in a surprising open-coiled “banana-shaped” shell
- Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics
- Identifying 17-β-HSD3 Deficiency in Patients with Karyotype 46,XY Misdiagnosed with Androgen Insensitivity Syndrome: A Pediatric Case Report
- 5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression
- Synthesis and 5α-reductase inhibitory activity of 8-substituted benzo[ƒ]quinolinones derived from palladium mediated coupling reactions
- Metabolic effects of 5α-reductase inhibition in humans
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
- Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
- Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
- Activated Polyamine Catabolism Depletes Acetyl-CoA Pools and Suppresses Prostate Tumor Growth in TRAMP Mice
- The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
- Prostate Cancer Early Detection, Version 2.2015
- Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
- The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
- Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases